- °ßÀû ¹× ÁÖ¹®
- ½ÇÇèÁ¤º¸
- Á¦Ç°/½ÇÇè Q&A
- Ŭ·¹ÀÓ
|
|
|
|
SARS-CoVÀÇ homology¿Í 80% ÀÏÄ¡ÇÏ´Â COVID-19´Â, ÃÖ±Ù ¿¬±¸¿¡ µû¸£¸é human mucosal Ç¥¸éÀÇ ACE2¿¡ virus Ç¥¸éÀÇ spike°¡ binding µÇ¾î virus°¡ ¼÷ÁÖ¼¼Æ÷¿¡ °áÇյǴ mechanismÀ¸·Î ÀÌ·¯ÇÑ mechanismÀº antiviral ¾à¹° Ä¡·á¸¦ À§ÇÑ targetÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, COVID-19 ȯÀÚ Ç÷¾×¿¡¼ ¸é¿ª¼¼Æ÷ÀÇ Áõ°¡ ¶ÇÇÑ Áõ¸í ÇÏ¿´½À´Ï´Ù.
±âÁ¸ ¿¬±¸¸¦ ÅëÇØ ¿ªÇÒÀÌ È®ÀÎµÈ compound Áß COVID-19 ±âÀü°ú °ü·ÃÀÌ ÀÖ´Â ¾à¹°µéÀ» ¾È³»µå¸³´Ï´Ù. |
![]() |
||
TOCRIS |
¡¡ | Cat. No. | Product Name / Activity |
¡¡ | 4274 | AP 24534 |
¡¡ | ¡¡ | Identified as targeting human proteins in the SARS-CoV-2 interactome; potent multi-kinase and pan-Bcr-Abl inhibitor |
¡¡ | 7283 | Apilimod dimesylate |
¡¡ | ¡¡ | Inhibits cellular entry by SARS-CoV-2, MERS-CoV and MHV S pseudovirions; potent and selective PIKfyve inhibitor |
¡¡ | 7235 | Arbidol |
¡¡ | ¡¡ | Inhibits replication of SARS-CoV-2 in vitro; broad spectrum antiviral |
¡¡ | 6358 | Atovaquone |
¡¡ | ¡¡ | Exhibits anti-MERS-CoV activity in vitro; DHODH inhibitor |
¡¡ | 4600 | Auranofin |
¡¡ | ¡¡ | Inhibits SARS-CoV-2 infection in vitro |
¡¡ | 7222 | Baricitinib |
¡¡ | ¡¡ | In silico modelling predicts inhibition of SARS-CoV-2 cell entry; highly potent JAK inhibitor |
¡¡ | 3193 | Camostat mesylate |
¡¡ | ¡¡ | Inhibits entry of SARS-Cov-2 into lung cells; TMPRSS2 inhibitor |
¡¡ | 4109 | Chloroquine diphosphate |
¡¡ | ¡¡ | Inhibits SARS-CoV-2 infection in vitro |
¡¡ | 6357 | Ciclesonide |
¡¡ | ¡¡ | Inhibits replication of SARS-CoV-2 in vitro; glucocorticoid |
¡¡ | 0460 | Cinanserin hydrochloride |
¡¡ | ¡¡ | Inhibits replication of SARS-CoV; Mpro inhibitor and 5-HT2 antagonist |
¡¡ | 0970 | Cycloheximide |
¡¡ | ¡¡ | Exhibits anti-MERS-CoV activity in vitro; protein synthesis inhibitor |
¡¡ | 1101 | Cyclosporin A |
¡¡ | ¡¡ | Inhibits coronavirus replication; cyclophilin inhibitor |
¡¡ | 7223 | Dabrafenib mesylate |
¡¡ | ¡¡ | Targets human proteins in the SARS-CoV-2 interactome; potent and selective B-Raf, CDK16 and NEK9 inhibitor |
¡¡ | 1467 | Daunorubicin hydrochloride |
¡¡ | ¡¡ | Identified as targeting human proteins in the SARS-CoV-2 interactome; DNA topoisomerase II inhibitor |
¡¡ | 4583 | Digoxin |
¡¡ | ¡¡ | Exhibits anti-MERS-CoV activity in vitro; Na+/K+ ATPase inhibitor |
¡¡ | 3807 | Disulfiram |
¡¡ | ¡¡ | SARS-CoV-2 Mpro inhibitor; also reversibly stimulates SERCA Ca2+-ATPase |
¡¡ | 4545 | E 64d |
¡¡ | ¡¡ | Inhibts entry of SARS-CoV-2 into lung cells in combination with Camostat (Cat. No. 3193); cathepsin inhibitor |
¡¡ | 3631 | FK 506 |
¡¡ | ¡¡ | Identified as targeting human proteins in the SARS-CoV-2 interactome; potent calcineurin inhibitor |
¡¡ | 3259 | Gemcitabine hydrochloride |
¡¡ | ¡¡ | Inhibits replication of coronaviruses; DNA synthesis inhibitor |
¡¡ | 7280 | GRL 0617 |
¡¡ | ¡¡ | Coronavirus PLpro inhibitor |
¡¡ | 7227 | GS 441524 |
¡¡ | ¡¡ | Displays antiviral activity against MERS-CoV, SARS-CoV and SARS-CoV-2; viral RNA-dependent RNA polymerase (RdRp) inhibitor; active metabolite of Remdesivir (Cat. No. 7226) |
¡¡ | 1416 | Homoharringtonine |
¡¡ | ¡¡ | Inhibits SARS-CoV-2 infection in vitro; inhibits protein synthesis |
¡¡ | 5648 | Hydroxychloroquine sulfate |
¡¡ | ¡¡ | Inhibits SARS-CoV-2 viral infection in vitro |
¡¡ | 1708 | Indomethacin |
¡¡ | ¡¡ | Identified as targeting human proteins in the SARS-CoV-2 interactome |
¡¡ | 1260 | Ivermectin |
¡¡ | ¡¡ | Inhibits replication of SARS-Cov-2 in vitro; antiparasitic and antiviral |
¡¡ | 2959 | Lercanidipine hydrochloride |
¡¡ | ¡¡ | Exhibits anti-MERS-CoV activity in vitro; CaV1.x blocker |
¡¡ | 3765 | Linezolid |
¡¡ | ¡¡ | Identified as targeting human proteins in the SARS-CoV-2 interactome; antibiotic |
¡¡ | 0840 | Loperamide hydrochloride |
¡¡ | ¡¡ | Inhibits replication of coronaviruses in vitro; peripherally acting μ opioid agonist and Ca2+ channel blocker |
¡¡ | 7052 | Lopinavir |
¡¡ | ¡¡ | Inhibits SARS-CoV-2 replication in vitro; highly potent and selective HIV-1 protease inhibitor |
¡¡ | 6819 | Mefloquine hydrochloride |
¡¡ | ¡¡ | Exhibits antiviral activities against SARS-CoV-2; also Cx36 and Cx50 gap channel blocker |
¡¡ | 2864 | Metformin hydrochloride |
¡¡ | ¡¡ | Identified as targeting human proteins in the SARS-CoV-2 interactome; antidiabetic |
¡¡ | 7230 | MPro N3 |
¡¡ | ¡¡ | Coronavirus Mpro inhibitor |
¡¡ | 3766 | Nelfinavir mesylate |
¡¡ | ¡¡ | Exhibits anti-MERS-CoV activity in vitro; potent HIV-1 protease inhibitor |
¡¡ | 2583 | Omeprazole |
¡¡ | ¡¡ | Enhances anti-SARS-CoV-2 activity of serine protease inhibitors |
¡¡ | 1076 | Ouabain |
¡¡ | ¡¡ | Exhibits anti-MERS-CoV activity in vitro; Na+/K+ ATPase inhibitor |
¡¡ | 1125 | Quercetin |
¡¡ | ¡¡ | Inhibits SARS-CoV Mpro; also non-selective PI 3-kinase inhibitor |
¡¡ | 1292 | Rapamycin |
¡¡ | ¡¡ | Inhibits MERS-CoV infection; mTOR inhibitor and immunosuppressant |
¡¡ | 7226 | Remdesivir |
¡¡ | ¡¡ | Displays antiviral activity against MERS-CoV, SARS-CoV and SARS-CoV-2; viral RNA-dependent RNA polymerase (RdRp) inhibitor |
¡¡ | 4501 | Ribavirin |
¡¡ | ¡¡ | Inhibits cytopathic effect of SARS-CoV in vitro; guanosine analog and IMPDH inhibitor |
¡¡ | 7064 | Ruxolitinib |
¡¡ | ¡¡ | Targets human proteins in the SARS-CoV-2 interactome; potent and selective JAK1/JAK2 inhibitor |
¡¡ | 7191 | Santacruzamate A |
¡¡ | ¡¡ | Identified as targeting human host proteins that interact with SARS-CoV-2 |
¡¡ | 7189 | Saracatinib |
¡¡ | ¡¡ | Inhibits MERS-CoV, other coronaviruses and dengue virus |
¡¡ | 2815 | Valproic acid, sodium salt |
¡¡ | ¡¡ | Identified as targeting human proteins in the SARS-CoV-2 interactome; HDAC inhibitor |
¡¡ | 0654 | Verapamil hydrochloride |
¡¡ | ¡¡ | Targets human proteins in the SARS-CoV-2 interactome; CaV1.x blocker |
¡¡ | ¡¡ |
ACE Small Molecule Compound | ||
Cat.No. | Product | Description |
2578 | Benazepril hydrochloride | ACE inhibitor |
4302 | Perindopril erbumine | ACE inhibitor |
4455 | Captopril | ACE inhibitor also inhibits LTA4 hydrolase |
¡¡ | ¡¡ | ¡¡ |
Cathepsin B/L Small Molecule Compounds | ||
Cat.No. | Product | Description |
0448 | Calpeptin | Calpain and cathepsin L inhibitor |
3625 | SID 26681509 | Cathepsin L inhibitor |
4863 | CA 074 | Selective cathepsin B inhibitor |
0384 | N-Acetyl-L-leucyl- L-leucyl-L-methional |
Cathepsin inhibitor |
4545 | E 64d | Cathepsin inhibitor; interferes with autolysosomal digestion |
1146 | MDL 28170 | Potent and selective Calpain and Cathepsin B inhibitor |
¡¡ | ¡¡ | ¡¡ |
IL-1 beta Small Molecule Compound | ||
Cat.No. | Product | Description |
1793 | AF 12198 | potent, selective human type IL-1 receptor antagonist |
¡¡ | ¡¡ | ¡¡ |
TNF-alpha Small Molecule Compound | ||
Cat.No. | Product | Description |
5484 | C 87 | TNF-α inhibitor |
¡¡ | ¡¡ | ¡¡ |
VEGFR-2 Small Molecule Compounds | ||
Cat.No. | Product | Description |
3882 | (E)-FeCP-oxindole | Selective VEGFR-2 inhibitor |
2542 | Ki 8751 | potent, selective VEGFR-2 inhibitor |
Aminopeptidase Small Molecule Compounds | ||
Cat.No. | Product | Description |
3595 | CHR 2797 | Aminopeptidase inhibitor, also called Tosedostat |
¡¡ | ¡¡ | ¡¡ |
DPPIV/CD26 Small Molecule Compounds | ||
Cat.No. | Product | Description |
2783 | DPPI 1c | DPPIV/CD26 inhibitor |
2790 | K 579 | DPPIV/CD26 inhibitor |
3506 | NVP DPP 728 | Potent DPPIV/CD26 inhibitor; orally active |
6507 | Saxagliptin | High affinity DPPIV/CD26 inhibitor; active in vivo |
¡¡ | ¡¡ | ¡¡ |
Human Neutrophil Elastase 1 (HNE1) Small Molecule Compounds | ||
Cat.No. | Product | Description |
5651 | ONO 6818 | High affinity and selective Human Neutrophil Elastase 1 (HNE1) inhibitor; orally active |
5706 | BAY 678 | Potent Human Neutrophil Elastase (HNE) inhibitor; cell permeable |
6389 | BAY 677 | Inactive control for BAY 678 (Catalog # 5706) |
¡¡ | ¡¡ | ¡¡ |
Furin Small Molecule Compounds | ||
Cat.No. | Product | Description |
1793 | AF 12198 | Potent Furin inhibitor |
¡¡ | ¡¡ | ¡¡ |
TMPRSS2 Small Molecule Compounds | ||
Cat.No. | Product | Description |
3193 | Camostat | TMPRSS2 inhibitor |
3081¡¡ |
Nafamostat¡¡ |
Inhibits SARS-CoV-2 infection in vitro ¡¡ |
Autophagy Small Molecule Compounds | ||
Cat.No. | Product | Description |
5648 | Hydroxychloroquine sulfate | Autophagy inhibitor, also inhibits TLR9; inhibits SARS-CoV-2 viral infection |
¡¡ | ¡¡ | ¡¡ |
Topo I inhibitor | ||
Cat. No. | product | size |
TG4100 | Topotecan Hydrochloride (Hycamtin) |
0.25 mL |
TG4101 | Irinotecan (CPT-11) | 0.25 mL |
TG4110 | Camptothecin | 0.25 mL |
¡¡ | ¡¡ | ¡¡ |
Topo II inhibitor | ||
Cat. No. | product | size |
TG4140 | Etoposide (VP16) | 0.25 mL |
¢¹ There is current research linking the inhibition of topoisomerase and the "cytokine storm" that follows SAR CoV2 infections (COVID-19). |
¢º Drug Repurposing (¾à¹°ÀçâÃâ) : Tocriscreen Compound Library º¸·¯°¡±â |
¡¡ | SARS-CoV-2 Viral Lifecyle. Host cell entry is effected by the binding of receptor binding domain (RBD) of the spike (S) protein on the nucleocapsid to ACE2, a protease on the host cell surface. The binding of the S protein to ACE2 is facilitated by another host cell protease, TMPRSS2 (transmembrane protease, serine 2). Following binding of S protein the virus is internalized. The internalized virus is uncoated and the SARS-CoV-2 genome is released into the cytoplasm. The viral RNA is then replicated and translated. This generates two polyproteins PP1A and PP1AB. These proteins contain within their sequence, papain-like protease (PLpro) and the coronavirus main protease (Mpro, also known as 3CLpro), which cleave the polyproteins into a variety of other functional proteins. The viral RNA also encodes the structural components of the virus, i.e. spike, nucleocapsid, membrane and envelope proteins. Following reproduction of all the viral components, coronavirus is assembled and released via vesicular exocytosis. |
COPYRIGHT(c) 2008. °í¸¶¹ÙÀÌ¿ÀÅØ(ÁÖ). ALL RIGHTS RESERVED. Contact Webmaster for more information.
°³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ (07207) ¼¿ï½Ã ¿µµîÆ÷±¸ ¾çÆò·Î 21±æ 26 ¼±À¯µµ¿ª1Â÷ ¾ÆÀÌ¿¡½ººñÁö 19Ãþ | TEL 02)579-8787 | FAX 02)578-7042.